Related Experiment Video
Updated: Aug 5, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in
1Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Campus, Aurora, CO, USA.
Abstract:
Continuous ketone monitoring (CKM) may address the principal barrier to adjunctive sodium-glucose cotransporter-2 inhibitor use in type 1 diabetes: Unrecognized ketosis and euglycemic diabetic ketoacidosis. Unlike conventional urine or capillary ketone testing, CKM provides real-time β-hydroxybutyrate trends and may identify rising ketones before clinical symptoms. Emerging dual glucose-ketone sensors could improve risk stratification, support earlier intervention, refine ketone mitigation protocols, and potentially integrate with automated insulin delivery systems. Although promising, CKM remains an emerging technology. Studies are needed to define actionable thresholds, validate outcomes, and determine whether it can safely expand the use of adjunctive therapies in type 1 diabetes.
Related Concept Videos
Diabetic Ketoacidosis l: Introduction
Diabetes Mellitus: Type 2 and Gestational
Diabetic Ketoacidosis ll: Pathophysiology
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction
Type II Diabetes I: Introduction
